Efficacy of tolvaptan in a patient with right-sided heart failure and renal dysfunction refractory to diuretic therapy

Yumiko Joko, Nobuhiro Ikemura, Kotaro Miyata, Yasuyuki Shiraishi, Hiroaki Tanaka, Takuo Yoshida, Yukinori Ikegami, Jun Fuse, Munehisa Sakamoto, Yukihiko Momiyama

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The use of loop diuretics has been shown to deteriorate renal dysfunction and is associated with a poor prognosis in patients with heart failure (HF). Tolvaptan, a vasopressin V2-receptor antagonist, has been reported to be effective in treating HF due to its potent effects of water diuresis and is expected to improve fluid retention without adversely affecting renal function. The present case is a 77-year-old man with pulmonary hypertension associated with chronic pulmonary artery thrombosis and old pulmonary tuberculosis who developed worsening right-sided HF with marked fluid retention and renal dysfunction. In this case, tolvaptan was effective in improving HF without deteriorating the patient's renal dysfunction.<. Learning objective: Tolvaptan is effective in treating patients with right-sided heart failure associated with marked fluid retention and renal dysfunction who are refractory to loop diuretics and can improve and control heart failure symptoms without worsening renal dysfunction.>.

Original languageEnglish
Pages (from-to)226-229
Number of pages4
JournalJournal of Cardiology Cases
Volume9
Issue number6
DOIs
Publication statusPublished - 2014 Jun
Externally publishedYes

Fingerprint

Patient Rights
Diuretics
Heart Failure
Kidney
Sodium Potassium Chloride Symporter Inhibitors
Vasopressin Receptors
Diuresis
Therapeutics
Pulmonary Tuberculosis
Pulmonary Hypertension
Pulmonary Artery
Thrombosis
tolvaptan
Water

Keywords

  • Diuretics
  • Heart failure
  • Pulmonary hypertension
  • Renal dysfunction
  • Tolvaptan

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Efficacy of tolvaptan in a patient with right-sided heart failure and renal dysfunction refractory to diuretic therapy. / Joko, Yumiko; Ikemura, Nobuhiro; Miyata, Kotaro; Shiraishi, Yasuyuki; Tanaka, Hiroaki; Yoshida, Takuo; Ikegami, Yukinori; Fuse, Jun; Sakamoto, Munehisa; Momiyama, Yukihiko.

In: Journal of Cardiology Cases, Vol. 9, No. 6, 06.2014, p. 226-229.

Research output: Contribution to journalArticle

Joko, Y, Ikemura, N, Miyata, K, Shiraishi, Y, Tanaka, H, Yoshida, T, Ikegami, Y, Fuse, J, Sakamoto, M & Momiyama, Y 2014, 'Efficacy of tolvaptan in a patient with right-sided heart failure and renal dysfunction refractory to diuretic therapy', Journal of Cardiology Cases, vol. 9, no. 6, pp. 226-229. https://doi.org/10.1016/j.jccase.2014.02.003
Joko, Yumiko ; Ikemura, Nobuhiro ; Miyata, Kotaro ; Shiraishi, Yasuyuki ; Tanaka, Hiroaki ; Yoshida, Takuo ; Ikegami, Yukinori ; Fuse, Jun ; Sakamoto, Munehisa ; Momiyama, Yukihiko. / Efficacy of tolvaptan in a patient with right-sided heart failure and renal dysfunction refractory to diuretic therapy. In: Journal of Cardiology Cases. 2014 ; Vol. 9, No. 6. pp. 226-229.
@article{3b5936ff860a4bf4aaa22683aaddfeab,
title = "Efficacy of tolvaptan in a patient with right-sided heart failure and renal dysfunction refractory to diuretic therapy",
abstract = "The use of loop diuretics has been shown to deteriorate renal dysfunction and is associated with a poor prognosis in patients with heart failure (HF). Tolvaptan, a vasopressin V2-receptor antagonist, has been reported to be effective in treating HF due to its potent effects of water diuresis and is expected to improve fluid retention without adversely affecting renal function. The present case is a 77-year-old man with pulmonary hypertension associated with chronic pulmonary artery thrombosis and old pulmonary tuberculosis who developed worsening right-sided HF with marked fluid retention and renal dysfunction. In this case, tolvaptan was effective in improving HF without deteriorating the patient's renal dysfunction.<. Learning objective: Tolvaptan is effective in treating patients with right-sided heart failure associated with marked fluid retention and renal dysfunction who are refractory to loop diuretics and can improve and control heart failure symptoms without worsening renal dysfunction.>.",
keywords = "Diuretics, Heart failure, Pulmonary hypertension, Renal dysfunction, Tolvaptan",
author = "Yumiko Joko and Nobuhiro Ikemura and Kotaro Miyata and Yasuyuki Shiraishi and Hiroaki Tanaka and Takuo Yoshida and Yukinori Ikegami and Jun Fuse and Munehisa Sakamoto and Yukihiko Momiyama",
year = "2014",
month = "6",
doi = "10.1016/j.jccase.2014.02.003",
language = "English",
volume = "9",
pages = "226--229",
journal = "Journal of Cardiology Cases",
issn = "1878-5409",
publisher = "Elsevier Limited",
number = "6",

}

TY - JOUR

T1 - Efficacy of tolvaptan in a patient with right-sided heart failure and renal dysfunction refractory to diuretic therapy

AU - Joko, Yumiko

AU - Ikemura, Nobuhiro

AU - Miyata, Kotaro

AU - Shiraishi, Yasuyuki

AU - Tanaka, Hiroaki

AU - Yoshida, Takuo

AU - Ikegami, Yukinori

AU - Fuse, Jun

AU - Sakamoto, Munehisa

AU - Momiyama, Yukihiko

PY - 2014/6

Y1 - 2014/6

N2 - The use of loop diuretics has been shown to deteriorate renal dysfunction and is associated with a poor prognosis in patients with heart failure (HF). Tolvaptan, a vasopressin V2-receptor antagonist, has been reported to be effective in treating HF due to its potent effects of water diuresis and is expected to improve fluid retention without adversely affecting renal function. The present case is a 77-year-old man with pulmonary hypertension associated with chronic pulmonary artery thrombosis and old pulmonary tuberculosis who developed worsening right-sided HF with marked fluid retention and renal dysfunction. In this case, tolvaptan was effective in improving HF without deteriorating the patient's renal dysfunction.<. Learning objective: Tolvaptan is effective in treating patients with right-sided heart failure associated with marked fluid retention and renal dysfunction who are refractory to loop diuretics and can improve and control heart failure symptoms without worsening renal dysfunction.>.

AB - The use of loop diuretics has been shown to deteriorate renal dysfunction and is associated with a poor prognosis in patients with heart failure (HF). Tolvaptan, a vasopressin V2-receptor antagonist, has been reported to be effective in treating HF due to its potent effects of water diuresis and is expected to improve fluid retention without adversely affecting renal function. The present case is a 77-year-old man with pulmonary hypertension associated with chronic pulmonary artery thrombosis and old pulmonary tuberculosis who developed worsening right-sided HF with marked fluid retention and renal dysfunction. In this case, tolvaptan was effective in improving HF without deteriorating the patient's renal dysfunction.<. Learning objective: Tolvaptan is effective in treating patients with right-sided heart failure associated with marked fluid retention and renal dysfunction who are refractory to loop diuretics and can improve and control heart failure symptoms without worsening renal dysfunction.>.

KW - Diuretics

KW - Heart failure

KW - Pulmonary hypertension

KW - Renal dysfunction

KW - Tolvaptan

UR - http://www.scopus.com/inward/record.url?scp=84901635164&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901635164&partnerID=8YFLogxK

U2 - 10.1016/j.jccase.2014.02.003

DO - 10.1016/j.jccase.2014.02.003

M3 - Article

AN - SCOPUS:84901635164

VL - 9

SP - 226

EP - 229

JO - Journal of Cardiology Cases

JF - Journal of Cardiology Cases

SN - 1878-5409

IS - 6

ER -